Literature DB >> 10968496

Optimal asthma control, starting with high doses of inhaled budesonide.

H K Reddel1, C R Jenkins, G B Marks, S I Ware, W Xuan, C M Salome, C A Badcock, A J Woolcock.   

Abstract

The aim of this study was to determine whether outcomes in poorly controlled asthma can be further improved with a starting dose of inhaled budesonide higher than that recommended in international guidelines. The study had a parallel-group design and included 61 subjects with poorly controlled asthma, randomized to receive 3,200 microg or 1,600 microg budesonide daily by Turbuhaler for 8 weeks (double-blind), then 1,600 microg x day(-1) for 8 weeks (single-blind), followed by 14 months of open-label budesonide dose down-titration using a novel algorithm, with a written asthma crisis plan based on electronic peak expiratory flow monitoring. The primary outcome variable for weeks 1-16 was change in airway hyperresponsiveness (AHR), and, for the open-label phase, mean daily budesonide dose. By week 16, there were large changes from baseline in all outcomes, with no significant differences between the 3,200- and 1,600-microg x day(-1) starting dose groups (AHR increased by 3.2 versus 3.0 doubling doses, p=0.7; morning peak flow increased by 134 versus 127 L x min(-1), p=0.8). Subjects starting with 3,200 microg x day(-1) were 3.8 times more likely to achieve AHR within the normal range, as defined by a provocative dose of histamine causing a 20% fall in forced expiratory volume in one second (PD20) of > or = 3.92 micromol by week 16 (p=0.03) [corrected]. During dose titration, there was no significant difference in mean budesonide dose (1,327 versus 1,325 microg x day(-1), p>0.3). Optimal asthma control was achieved in the majority of subjects (at completion/withdrawal: median symptoms 0.0 days x week(-1), beta2-agonist use 0.2 occasions x day(-1), and PD20 2.4 micromol). In subjects with poorly controlled asthma, a starting dose of 1,600 microg x day(-1) budesonide was sufficient to lead to optimal control in most subjects. The high degree of control achieved, compared with previous studies, warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10968496     DOI: 10.1034/j.1399-3003.2000.16b08.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

1.  Analysis of adherence to peak flow monitoring when recording of data is electronic.

Authors:  Helen K Reddel; Brett G Toelle; Guy B Marks; Sandra I Ware; Christine R Jenkins; Ann J Woolcock
Journal:  BMJ       Date:  2002-01-19

2.  Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma.

Authors:  D B Price; D Hernandez; P Magyar; J Fiterman; K M Beeh; I G James; S Konstantopoulos; R Rojas; J A van Noord; M Pons; L Gilles; J A Leff
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

3.  Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation.

Authors:  C M Salome; J D Leuppi; R Freed; G B Marks
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

4.  When can personal best peak flow be determined for asthma action plans?

Authors:  H K Reddel; G B Marks; C R Jenkins
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

Review 5.  Long-acting beta2-agonists in asthma: not so SMART?

Authors:  Graeme P Currie; Daniel K C Lee; Brian J Lipworth
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 6.  Pharmacotherapy of critical asthma syndrome: current and emerging therapies.

Authors:  T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

Review 7.  Mechanisms of airway hyper-responsiveness in asthma: the past, present and yet to come.

Authors:  D G Chapman; C G Irvin
Journal:  Clin Exp Allergy       Date:  2015-04       Impact factor: 5.018

Review 8.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 9.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

10.  Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients.

Authors:  Graeme P Currie; Caroline E Bates; Daniel K C Lee; Catherine M Jackson; Brian J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  2003-03-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.